Three of the world's largest drugmakers dialed up their R&D budgets in 2014, as Novartis, Pfizer and Bristol-Myers Squibb spent big on costly late-stage programs with hopes of delivering blockbuster new treatments in the coming year.
Bristol-Myers Squibb took a top-line hit in 2014, but that's mostly because it sold its share of a diabetes alliance to partner AstraZeneca. This year, it's looking for an even bigger slide--with no big divestment to blame.
Chief Operating Officer Giovanni Caforio will take over the top exec job at Bristol-Myers Squibb on May 5, when 64-year-old Lamberto Andreotti steps down from the role he has held for 5 years and takes over instead as executive chairman of the board.
Eli Lilly is buying big into the idea that the latest and greatest cancer therapies can work even better in combination, inking agreements to study its drugs alongside immunotherapies from Merck and Bristol-Myers Squibb.
Bristol-Myers Squibb and Merck & Co. rolled out some juicy news about their cancer immunotherapies as the JPMorgan Healthcare Conference got into full swing. And the tit-for-tat press releases turned up the spotlight on one of the most closely watched drug match-ups on the market.
Bristol-Myers Squibb's standout immuno-oncology drug nivolumab, approved last month as Opdivo, scored a resounding success in a late-stage lung cancer trial, bolstering sales expectations for the pioneering treatment.
Bristol-Myers Squibb just snagged U.S. approval for its new PD-1 cancer immunotherapy Opdivo, but already is building some momentum for the drug it expects to lead its growth this year. Just two weeks after the FDA gave the melanoma drug an early approval, the U.K.s Medicines and Healthcare products Regulatory Agency (MHRA), has tagged it with designation that could lead to early approval there.
If you've watched television lately, you know that Pfizer and Bristol-Myers have been spending a lot of money on advertising to back their new anticoagulant, Eliquis. So have rival Boehringer Ingelheim, with its Pradaxa drug, and Bayer and Johnson & Johnson with Xarelto.
Bristol-Myers Squibb is turning to the California Institute for Biomedical Research (Calibr) in San Diego for new fibrosis drug candidates.
Bristol-Myers scored FDA approval for its cancer immunotherapy Opdivo (nivolumab) three months ahead of schedule, setting it up for a head-to-head contest against Merck's recent debut in the same class, Keytruda.